Tag: autism (page 1 of 2)

the effects of bad science

Vaccination

A new epidemic of measles has broken out in Wales. Vaccination rates fell after a paper linking the vaccine to autism was published in the 1998. The paper was later proven to be fraudulent. NPR reports:

More than 1,200 people have come down with measles so far this year, following nearly 2,000 cases in 2012. Many of the cases have been in Wales.

Childhood vaccination rates plummeted in Great Britain after a 1998 paper by Dr. Andrew Wakefield claimed that the vaccine for measles, mumps and rubella had caused autism in a dozen children. That study has since been proven , but it fueled fears about vaccine safety in Great Britain and the United States.

“This is the legacy of the Wakefield scare,” Dr. David Elliman, spokesman for the Royal College of Pediatrics and Child Health, told The Associated Press.

Most of the measles cases have been in children and teenagers between the ages of 10 and 18, according to British health officials. In that age group, vaccination rates dropped below 50 percent in some parts of England after the Wakefield paper was published.

arbaclofen and autism

Arbaclofen

Arbaclofen shows promise as a treatment for Fragile X syndrome and autism.

An experimental drug called arbaclofen has helped improve outcomes in patients with Fragile X syndrome. Fragile X syndrome causes cognitive and social dysfunctions that are similar to autism. Researchers are hoping this treatment may have broader applicability,  though that remains to be seen. From NPR:

An experimental drug that helps people who have Fragile X syndrome is raising hopes of a treatment for autism.

The drug, called arbaclofen, made people with Fragile X less likely to avoid social interactions, according to a study in Science Translational Medicine. Researchers suspect it might do the same for people with autism.

Arbaclofen appears to work by tamping down overactive brain signals that can make it hard to navigate social interactions.

There’s a good chance it will help people with autism unrelated to Fragile X because they have similar problems with social interactions, says Mark Bear, a researcher at MIT and a co-founder of Seaside Therapeutics, which makes arbaclofen.

“It would be, I think, unrealistic to expect that this drug would be uniformly beneficial to all people that have an autism diagnosis,” Bear says. “But I think we can still be quite optimistic that it can be beneficial to a subset of those patients.”

branched-chain amino acid deficiency linked to rare form of autism

Lots of interesting reads in Scientific American & Nature these past few weeks.  Ewen Callaway of Nature magazine brings us this story:

A rare, hereditary form of autism has been found — and it may be treatable with protein supplements.

Genome sequencing of six children with autism has revealed mutations in a gene that stops several essential amino acids being depleted. Mice lacking this gene developed neurological problems related to autism that were reversed by dietary changes, a paper published today in Scienceshows1.

“This might represent the first treatable form of autism,” says Joseph Gleeson, a child neurologist at the University of California, San Diego, who led the study. “That is both heartening to families with autism, and also I think revealing of the underlying mechanisms of autism.”

The children came from three families with Middle Eastern ancestry; in each case the parents were first cousins. Studying such families makes the hunt for the rare recessive mutations underlying some forms of autism simpler than it would be among the general population, Gleeson says, because the odds are higher that children will be born with two copies of the recessive mutation.

In each family, Gleeson’s team identified mutations that inactivate the enzyme BCKD-kinase, which normally prevents the body from breaking down branched-chain amino acids called leucine, isoleucine and valine after a meal. Humans cannot synthesize these amino acids and must obtain them from food.

“We predicted that patients would burn through these amino acids,” says Gleeson. The prediction was correct: after eating, the children had low blood levels of the branched-chain amino acids. Mice lacking the gene that codes for BCKD-kinase also had low levels of the amino acids in their blood and tissue.

The sample size of six is extremely limited due to the rarity of the disease, so we don’t know if the result are generalizable. But the results are interesting nonetheless.

//phukrauwhugn.net/4/4535925